PB 90 of 2025

National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 7) 2025

I, Rebecca Richardson, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.

Dated                28    July 2025    

REBECCA RICHARDSON

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1  Name

 (1) This instrument is the National Health (Listed Drugs on F1 or F2) Amendment Determination (No. 7) 2025.

 (2) This instrument may also be cited as PB 90 of 2025.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 85AB(1) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1.         Schedule 1, after item dealing with Degarelix        

Omit:  

Denosumab  

1.         Schedule 1, after item dealing with Edaravone         

Insert:

    Eflornithine

1.         Schedule 1, after item dealing with Formoterol         

Insert:  

Foslevodopa with foscarbidopa

1.         Schedule 1, after item dealing with Upadacitinib          

Omit:  

Ustekinumab

1.         Schedule 2, after item dealing with Deferasirox           

Insert:  

Denosumab

1.         Schedule 2, after item dealing with Doxycycline            

Insert:  

Drospirenone with ethinylestradiol

1.         Schedule 2, after item dealing with Ursodeoxycholic acid           

Insert:  

Ustekinumab